Bruker

The company reported revenues of $414.9 million as acquisitions boosted revenues 6 percent and foreign exchange rates lowered them by 2 percent.

The platform received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia, and molds.

The new version of the mass spectrometry-based system adds 144 microbial species to its database and includes new tools for sample preparation.

While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.

With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.

The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.

The deal gives BD global distribution rights for several Bruker MALDI Biotyper products, expanding a 2010 agreement key to both firms' microbiology businesses.

The company reported total revenues of $384.9 million, up from $375.4 million for the first quarter of 2016 and above analysts' consensus estimate of $372.7 million.

Presented this week at the ECCMID annual meeting, the method uses mass spec to detect alterations to bacteria lipopolysaccharides that confer resistance.

The company reported revenues of $470.3 million, down from $478.2 million in Q4 2015 but beating the average analysts' estimate of $464.5 million.

Pages

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.